Integrated Pathways of Candida albicans Revealing Potential Targets and Key Factors Accountable for Pathogenicity

被引：1
作者：
Mishra S. [1 ]
Aier I. [1 ]
Varadwaj P. [1 ]
Misra K. [1 ]
机构：
[1] Indian Institute of Information Technology, Allahabad
来源：
Proceedings of the National Academy of Sciences, India Section B: Biological Sciences | 2019年 / 89卷 / 2期
关键词：
Candida albicans; Filamentation; Pathways; Ras1-pka pathway;
D O I：
10.1007/s40011-018-0964-2
中图分类号：
学科分类号：
摘要：
Candida albicans is one of the most opportunistic commensal fungus of human biome found normally in gastrointestinal cavity of healthy humans. Its dimorphic character provides the easy switching of yeast to filamentous form. However, in immunocompromised patients, blood-stream infections often cause death, despite the use of anti-fungal therapies. Its dimorphic and highly adaptive properties make it even more pathogenic in nature. The hyphal growth causes virulence in Candida. There are many different pathways or factors responsible for the same in Candida albicans. It is thus paramount to see the relationship between the pathways and the key factors of pathogenicity. The common factors can be used to inhibit more than a single pathway at the same time. In the present work, systems biology approach has been employed to summarize all the pathways and common factors leading to yeast to hyphal transition in Candida. The study provides new and potential targets essential for antifungal drug discovery which is highly required against drug resistance. © 2018, The National Academy of Sciences, India.
引用
收藏
页码：575 / 584
页数：9
相关论文
共 21 条
  • [1] Cutler J.E., Putative virulence factors of Candida albicans, Annu Rev Microbiol, 45, 187-218, (1991)
  • [2] Fidel P.L., Sobel J.D., The role of cell-mediated immunity in candidiasis, Trends Microbiol, 2, pp. 202-205, (1994)
  • [3] Xiang M.J., Liu J.Y., Ni P.H., Wang S., Shi C., Wei B., Ni Y.X., Ge H.L., Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans, FEMS Yeast Res, 13, 4, pp. 386-393, (2013)
  • [4] O'Neill East M., Henderson J.T., Jevons S., Tioconazole in the treatment of fungal infections of the skin. An international clinical research program, Dermatologica, 166, pp. 20-33, (1983)
  • [5] Lackner T.E., Clissold S.P., Bifonazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses, Drugs, 38, 2, pp. 204-225, (1989)
  • [6] Whaley S.G., Berkow E.L., Rybak J.M., Nishimoto A.T., Barker K.S., David Rogers P., Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species, Front Microbiol, (2017)
  • [7] Song J.L., Harry J.B., Eastman R.T., Oliver B.G., White T.C., The Candida albicans lanosterol 14-alpha-demethylase (ERG11) gene promoter is maximally induced after prolonged growth with antifungal drugs, Antimicrob Agents Chemother, 48, 4, pp. 1136-1144, (2004)
  • [8] Michael C., Lorenz Gerald R.F., The glyoxylate cycle is required for fungal virulence, Nature, 412, pp. 83-86, (2001)
  • [9] Prieto D., Roman E., Correia I., Pla J., The HOG pathway is critical for the colonization of the mouse gastrointestinal tract by Candida albicans, PLoS ONE, 9, 1, (2014)
  • [10] Richardson M.D., Changing patterns and trends in systemic fungal infections, J Antimicrob Chemother, 56, pp. 5-11, (2005)
123